Last reviewed · How we verify

NCT04374214

Effect of Simvastatin as Pulpotomy Agent in Cariously Exposed Permanent Molars

Status unknown NA Last updated 5 May 2020
What this trial tests

NA trial testing Complete Pulpotomy using Mineral Trioxide Aggregate in Reversible Pulpitis in 56 participants. Status unknown.

Timeline
1 December 2018
Primary endpoint
30 April 2020
30 June 2020

Quick facts

Lead sponsorPostgraduate Institute of Dental Sciences Rohtak
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment56
Start date1 December 2018
Primary completion30 April 2020
Estimated completion30 June 2020
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Postgraduate Institute of Dental Sciences Rohtak

Who can join

Adults 15 to 40, any sex, with Reversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will compare the outcome of complete pulpotomy in mature permanent mandibular molars with deep carious lesions by using Mineral Trioxide Aggregate and Simvastatin -alpha tricalcium phosphate as medicament agent

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of Simvastatin on Success of Pulpotomy in Carious Permanent Molars With Symptomatic Irreversible Pulpitis: A Randomised Controlled Trial.
    Gehlot S, Kumar V, Mittal S, Duhan J, et al · · 2026 · PMID 41652862 · DOI 10.1111/aej.70062

Verify or expand the search:

Other recruiting trials for Reversible Pulpitis

Currently open trials in the same condition.

Other Postgraduate Institute of Dental Sciences Rohtak trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing